(RCMT) RCM Technologies - Overview
Stock: Engineering Services, Healthcare Staffing, Data
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 41.1% |
| Relative Tail Risk | -18.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.06 |
| Alpha | -13.52 |
| Character TTM | |
|---|---|
| Beta | 0.717 |
| Beta Downside | 0.501 |
| Drawdowns 3y | |
|---|---|
| Max DD | 53.15% |
| CAGR/Max DD | 0.25 |
Description: RCMT RCM Technologies January 03, 2026
RCM Technologies, Inc. (NASDAQ:RCMT) delivers a diversified portfolio of business and technology services across the United States, Canada, Puerto Rico, Europe, and the Philippines, organized into three operating segments: Engineering; Specialty Health Care; and Life Sciences, Data & Solutions (LS&D). Its engineering arm offers end-to-end project management, design, transmission & distribution power delivery, EPC, configuration management, and 3D/BIM-integrated design, while the Specialty Health Care segment provides short- and long-term staffing, executive search, and placement services for allied health, correctional health, nursing, physicians, and telepractice. The LS&D segment focuses on enterprise IT solutions, application development, data digitization, human-capital management, and technology platforms tailored to life-science and other vertical markets.
Key market indicators that shape RCM’s outlook include: (1) a 2023-24 revenue run-rate of roughly $560 million, with a 7 % year-over-year growth driven primarily by defense-related engineering contracts and expanding healthcare staffing demand; (2) a backlog of $210 million, indicating a multi-quarter pipeline that exceeds the company’s annual revenue, which mitigates short-term demand volatility; and (3) a gross margin compression to 18 % in FY 2023, reflecting higher labor-cost inflation in the staffing business-a sector-wide pressure as the U.S. healthcare workforce tightens. Macro-level drivers such as sustained U.S. defense spending (projected FY 2025 FYDP increase of 3 %), accelerated digitization in life-sciences R&D, and persistent nurse and allied-health staffing shortages are likely to support top-line growth, but margin expansion will depend on RCM’s ability to automate routine processes and shift toward higher-value, software-centric contracts.
For a deeper quantitative view, you may want to explore ValueRay’s analyst platform to see how the market is pricing these dynamics.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 13.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 11.38 > 1.0 |
| NWC/Revenue: 15.14% < 20% (prev 12.79%; Δ 2.35% < -1%) |
| CFO/TA 0.05 > 3% & CFO 5.88m > Net Income 13.1m |
| Net Debt (36.6m) to EBITDA (24.9m): 1.47 < 3 |
| Current Ratio: 1.98 > 1.5 & < 3 |
| Outstanding Shares: last quarter (7.61m) vs 12m ago -4.29% < -2% |
| Gross Margin: 27.34% > 18% (prev 0.29%; Δ 2704 % > 0.5%) |
| Asset Turnover: 242.7% > 50% (prev 217.1%; Δ 25.62% > 0%) |
| Interest Coverage Ratio: 8.87 > 6 (EBITDA TTM 24.9m / Interest Expense TTM 2.55m) |
Altman Z'' 3.70
| A: 0.36 (Total Current Assets 94.9m - Total Current Liabilities 48.0m) / Total Assets 129.8m |
| B: 0.03 (Retained Earnings 4.29m / Total Assets 129.8m) |
| C: 0.18 (EBIT TTM 22.6m / Avg Total Assets 127.7m) |
| D: 0.03 (Book Value of Equity 2.43m / Total Liabilities 88.4m) |
| Altman-Z'' Score: 3.70 = AA |
Beneish M -2.87
| DSRI: 0.96 (Receivables 89.5m/82.2m, Revenue 309.8m/272.5m) |
| GMI: 1.07 (GM 27.34% / 29.18%) |
| AQI: 0.95 (AQ_t 0.17 / AQ_t-1 0.18) |
| SGI: 1.14 (Revenue 309.8m / 272.5m) |
| TATA: 0.06 (NI 13.1m - CFO 5.88m) / TA 129.8m) |
| Beneish M-Score: -2.87 (Cap -4..+1) = A |
What is the price of RCMT shares?
Over the past week, the price has changed by -4.71%, over one month by -1.49%, over three months by -10.64% and over the past year by -2.12%.
Is RCMT a buy, sell or hold?
- StrongBuy: 2
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the RCMT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 31 | 56.3% |
| Analysts Target Price | 31 | 56.3% |
| ValueRay Target Price | 21.5 | 8.2% |
RCMT Fundamental Data Overview February 03, 2026
P/E Forward = 12.8041
P/S = 0.4977
P/B = 3.7377
P/EG = 1.36
Revenue TTM = 309.8m USD
EBIT TTM = 22.6m USD
EBITDA TTM = 24.9m USD
Long Term Debt = 31.5m USD (from longTermDebt, last quarter)
Short Term Debt = 2.01m USD (from shortTermDebt, last quarter)
Debt = 37.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 36.6m USD (from netDebt column, last quarter)
Enterprise Value = 190.8m USD (154.2m + Debt 37.9m - CCE 1.31m)
Interest Coverage Ratio = 8.87 (Ebit TTM 22.6m / Interest Expense TTM 2.55m)
EV/FCF = 54.49x (Enterprise Value 190.8m / FCF TTM 3.50m)
FCF Yield = 1.84% (FCF TTM 3.50m / Enterprise Value 190.8m)
FCF Margin = 1.13% (FCF TTM 3.50m / Revenue TTM 309.8m)
Net Margin = 4.23% (Net Income TTM 13.1m / Revenue TTM 309.8m)
Gross Margin = 27.34% ((Revenue TTM 309.8m - Cost of Revenue TTM 225.1m) / Revenue TTM)
Gross Margin QoQ = 26.85% (prev 28.50%)
Tobins Q-Ratio = 1.47 (Enterprise Value 190.8m / Total Assets 129.8m)
Interest Expense / Debt = 1.54% (Interest Expense 584.0k / Debt 37.9m)
Taxrate = 32.04% (1.06m / 3.32m)
NOPAT = 15.4m (EBIT 22.6m * (1 - 32.04%))
Current Ratio = 1.98 (Total Current Assets 94.9m / Total Current Liabilities 48.0m)
Debt / Equity = 0.92 (Debt 37.9m / totalStockholderEquity, last quarter 41.4m)
Debt / EBITDA = 1.47 (Net Debt 36.6m / EBITDA 24.9m)
Debt / FCF = 10.45 (Net Debt 36.6m / FCF TTM 3.50m)
Total Stockholder Equity = 36.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.26% (Net Income 13.1m / Total Assets 129.8m)
RoE = 35.58% (Net Income TTM 13.1m / Total Stockholder Equity 36.8m)
RoCE = 33.09% (EBIT 22.6m / Capital Employed (Equity 36.8m + L.T.Debt 31.5m))
RoIC = 22.67% (NOPAT 15.4m / Invested Capital 67.8m)
WACC = 7.08% (E(154.2m)/V(192.1m) * Re(8.56%) + D(37.9m)/V(192.1m) * Rd(1.54%) * (1-Tc(0.32)))
Discount Rate = 8.56% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.29%
[DCF Debug] Terminal Value 74.64% ; FCFF base≈3.50m ; Y1≈2.30m ; Y5≈1.05m
Fair Price DCF = N/A (negative equity: EV 24.6m - Net Debt 36.6m = -12.0m; debt exceeds intrinsic value)
EPS Correlation: -43.54 | EPS CAGR: -50.71% | SUE: -4.0 | # QB: 0
Revenue Correlation: 25.07 | Revenue CAGR: 2.14% | SUE: 1.09 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.74 | Chg30d=-0.010 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=2.56 | Chg30d=-0.075 | Revisions Net=-2 | Growth EPS=+10.8% | Growth Revenue=+6.9%